Rapamycin-mediated CD36 translational suppression contributes to alleviation of hepatic steatosis

Biochemical and Biophysical Research Communications

Volumn 447, Issue 1, 2014, Pages 57-63

  Wang, Chuan ^a   Yan, Yong ^a   Hu, Lin ^a   Zhao, Lei ^a   Yang, Ping ^a   Moorhead, John F ^b   Varghese, Zac ^b   Chen, Yaxi ^a   Ruan, Xiong Z ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

CD36; mTOR; NAFLD; Rapamycin; Translation

Indexed keywords

CD36 ANTIGEN; FATTY ACID; INITIATION FACTOR 4E; INITIATION FACTOR 4E BINDING PROTEIN 1; LONG CHAIN FATTY ACID; RAPAMYCIN; S6 KINASE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; FATTY LIVER; HUMAN; HUMAN CELL; LIPID DIET; LIPID LIVER LEVEL; LIPID STORAGE; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; WESTERN BLOTTING;

EUKARYOTA; MAMMALIA; MUS;

CD36; MTOR; NAFLD; RAPAMYCIN; TRANSLATION;

ANIMALS; ANTIGENS, CD36; DIET, HIGH-FAT; FATTY LIVER; HEP G2 CELLS; HUMANS; LIVER; MALE; MICE; MICE, INBRED C57BL; PALMITATES; SIROLIMUS;

EID: 84899472589     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.03.103     Document Type: Article

References (24)

1. X. Su, and N.A. Abumrad Cellular fatty acid uptake: a pathway under construction Trends Endocrinol. Metab. 20 2009 72 77
2. D. Greco, A. Kotronen, J. Westerbacka, O. Puig, P. Arkkila, T. Kiviluoto, S. Laitinen, M. Kolak, R.M. Fisher, A. Hamsten, P. Auvinen, and H. Yki-Jarvinen Gene expression in human NAFLD Am. J. Physiol. Gastrointest. Liver Physiol. 294 2008 G1281 G1287
3. D.J. Kennedy, S. Kuchibhotla, K.M. Westfall, R.L. Silverstein, R.E. Morton, and M. Febbraio A CD36-dependent pathway enhances macrophage and adipose tissue inflammation and impairs insulin signalling Cardiovasc. Res. 89 2011 604 613
4. J. Krammer, M. Digel, F. Ehehalt, W. Stremmel, J. Fullekrug, and R. Ehehalt Overexpression of CD36 and acyl-CoA synthetases FATP2, FATP4 and ACSL1 increases fatty acid uptake in human hepatoma cells Int. J. Med. Sci. 8 2011 599 614
5. D.P. Koonen, R.L. Jacobs, M. Febbraio, M.E. Young, C.L. Soltys, H. Ong, D.E. Vance, and J.R. Dyck Increased hepatic CD36 expression contributes to dyslipidemia associated with diet-induced obesity Diabetes 56 2007 2863 2871
6. M.E. Miquilena-Colina, E. Lima-Cabello, S. Sanchez-Campos, M.V. Garcia-Mediavilla, M. Fernandez-Bermejo, T. Lozano-Rodriguez, J. Vargas-Castrillon, X. Buque, B. Ochoa, P. Aspichueta, J. Gonzalez-Gallego, and C. Garcia-Monzon Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C Gut 60 2011 1394 1402
7. K.L. Ma, X.Z. Ruan, S.H. Powis, J.F. Moorhead, and Z. Varghese Anti-atherosclerotic effects of sirolimus on human vascular smooth muscle cells Am. J. Physiol. Heart Circ. Physiol. 292 2007 H2721 H2728
8. M.M. Elloso, N. Azrolan, S.N. Sehgal, P.L. Hsu, K.L. Phiel, C.A. Kopec, M.D. Basso, and S.J. Adelman Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo E-deficient mice Am. J. Transplant. 3 2003 562 569
9. M. Fraenkel, M. Ketzinel-Gilad, Y. Ariav, O. Pappo, M. Karaca, J. Castel, M.F. Berthault, C. Magnan, E. Cerasi, N. Kaiser, and G. Leibowitz MTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes Diabetes 57 2008 945 957
10. C. Chaveroux, L.J. Eichner, C.R. Dufour, A. Shatnawi, A. Khoutorsky, G. Bourque, N. Sonenberg, and V. Giguere Molecular and genetic crosstalks between mTOR and ERRalpha are key determinants of rapamycin-induced nonalcoholic fatty liver Cell Metab. 17 2013 586 598
11. H.L. Kenerson, M.M. Yeh, and R.S. Yeung Tuberous sclerosis complex-1 deficiency attenuates diet-induced hepatic lipid accumulation PLoS One 6 2011 e18075
12. K.L. Ma, X.Z. Ruan, S.H. Powis, Y. Chen, J.F. Moorhead, and Z. Varghese Sirolimus modifies cholesterol homeostasis in hepatic cells: a potential molecular mechanism for sirolimus-associated dyslipidemia Transplantation 84 2007 1029 1036
13. U.B. Pajvani, L. Qiang, T. Kangsamaksin, J. Kitajewski, H.N. Ginsberg, and D. Accili Inhibition of Notch uncouples Akt activation from hepatic lipid accumulation by decreasing mTorc1 stability Nat. Med. 19 2013 1054 1060
14. K.T. Pfaffenbach, A.M. Nivala, L. Reese, F. Ellis, D. Wang, Y. Wei, and M.J. Pagliassotti Rapamycin inhibits postprandial-mediated X-box-binding protein-1 splicing in rat liver J. Nutr. 140 2010 879 884
15. E.J. Jung, S.W. Kwon, B.H. Jung, S.H. Oh, and B.H. Lee Role of the AMPK/SREBP-1 pathway in the development of orotic acid-induced fatty liver J. Lipid Res. 52 2011 1617 1625
16. N. Hay, and N. Sonenberg Upstream and downstream of mTOR Genes. Dev. 18 2004 1926 1945
17. H.Y. Quan, Y. Kim do, S.J. Kim, H.K. Jo, G.W. Kim, and S.H. Chung Betulinic acid alleviates non-alcoholic fatty liver by inhibiting SREBP1 activity via the AMPK-mTOR-SREBP signaling pathway Biochem. Pharmacol. 85 2013 1330 1340
18. P. Garcia-Maceira, and J. Mateo Silibinin inhibits hypoxia-inducible factor-1alpha and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy Oncogene 28 2009 313 324
19. U. Chuluunbaatar, R. Roller, M.E. Feldman, S. Brown, K.M. Shokat, and I. Mohr Constitutive mTORC1 activation by a herpesvirus Akt surrogate stimulates mRNA translation and viral replication Genes. Dev. 24 2010 2627 2639
20. M. Pende, S.H. Um, V. Mieulet, M. Sticker, V.L. Goss, J. Mestan, M. Mueller, S. Fumagalli, S.C. Kozma, and G. Thomas S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5'-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway Mol. Cell. Biol. 24 2004 3112 3124
21. J. Zhou, M. Febbraio, T. Wada, Y. Zhai, R. Kuruba, J. He, J.H. Lee, S. Khadem, S. Ren, S. Li, R.L. Silverstein, and W. Xie Hepatic fatty acid transporter Cd36 is a common target of LXR PXR, and PPARgamma in promoting steatosis Gastroenterology 134 2008 556 567
22. A.A. Arbini, F. Guerra, M. Greco, E. Marra, L. Gandee, G. Xiao, Y. Lotan, G. Gasparre, J.T. Hsieh, and L. Moro Mitochondrial DNA depletion sensitizes cancer cells to PARP inhibitors by translational and post-translational repression of BRCA2 Oncogenesis 2 2013 e82
23. S. Pan, L. Huang, J. McPherson, D. Muzny, F. Rouhani, M. Brantly, R. Gibbs, and R.N. Sifers Single nucleotide polymorphism-mediated translational suppression of endoplasmic reticulum mannosidase I modifies the onset of end-stage liver disease in alpha1-antitrypsin deficiency Hepatology 50 2009 275 281
24. S. Wada, Y. Kato, M. Okutsu, S. Miyaki, K. Suzuki, Z. Yan, S. Schiaffino, H. Asahara, T. Ushida, and T. Akimoto Translational suppression of atrophic regulators by microRNA-23a integrates resistance to skeletal muscle atrophy J. Biol. Chem. 286 2011 38456 38465